Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSUBAKI
NCT02316821Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Dec 2014
- Primary completion
- May 2016
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) comparing bardoxolone methyl with Placebo (2 arms). Primary endpoints: Number and types of adverse events at 16 weeks and Change in glomerular filtration rate measured by inulin clearance at 16 weeks. Started Dec 2014; status: completed.
02
Drugs
bardoxolone methyl
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02316821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02316821.